Abstract: The current invention provides an enclosure that can be placed over a patient in order to contain bodily fluids. The device includes a clear plastic sheet that fits snugly over a frame. The sides of the device contain access ports for physicians or their instruments to enter the patient’s area. These ports may be holes or hanging strips of sheet that overlap so that they form a sufficient seal while also allowing easy access to the patient when pushed aside. The bottoms of the sheet may contain weights to hold the sheet down. There is the possibility of including filters or positive/negative air flow ports. The entire device may be disposable. The frame may be solid, or the frame may pop open like an enclosure or umbrella. The device may also have straps that can be tightened underneath the bed or stretcher to secure the entire device in place.

Abstract: Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described.

Abstract: Compounds of Formula (I): wherein R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted hererocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from, for example, hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is, for example, an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described.

Abstract: A skin barrier composition including a barrier component and an enzyme inhibiting component that is sprayable for use in ostomy and wound care, infant diapers, and fecal incontinence applications. The barrier component is based on petrolatum or other acceptable carriers, and the enzyme inhibitor component is derived from tubers, such as potatoes.

Abstract: The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is, halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.

Abstract: A process for chemically treating a metallic part such as a part used in aerospace applications comprising providing a process tank capable of receiving at least one part; providing at least one part to the process tank; providing an alkaline first solution into the process tank from a first storage tank; providing the first solution from the process tank into a transition tank; providing water to the process tank; providing the first solution from the transition tank into the first storage tank; providing an acidic second solution into the process tank from a second storage tank; providing the second solution into the transition tank; providing water to the process tank; providing the second solution into the second storage tank; providing a third coating solution having a pH of about 1.0 to about 3.0 into the process tank from a third storage tank; providing the third solution into the transition tank; providing water to the process tank; and providing the third solution into the third storage tank.